Salvage Radiotherapy for Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer: Dose-Response Analysis

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 3, 2010, Pages 735-740

  Bernard Jr , Johnny Ray ^a   Buskirk, Steven J ^a   Heckman, Michael G ^a   Diehl, Nancy N ^a   Ko, Stephen J ^a   Macdonald, Orlan K ^b   Schild, Steven E ^c   Pisansky, Thomas M ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Biochemical failure; Dose response; Prostate bed; Prostate specific antigen recurrence; Salvage

Indexed keywords

ANDROGEN SUPPRESSION; BIOCHEMICAL FAILURE; DOSE RESPONSE; DOSE-RESPONSE ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; HIGH DOSE; LOW DOSE; MULTIVARIABLE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RADICAL PROSTATECTOMY; RELATIVE RISKS; SALVAGE RADIOTHERAPY; SELECTION CRITERIA;

PEELING; RADIOTHERAPY;

ANTIGENS;

ANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CONTROLLED STUDY; DOSE RESPONSE; EXTERNAL BEAM RADIOTHERAPY; HORMONE INHIBITION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; SALVAGE THERAPY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TIME FACTORS;

EID: 76049130194     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.02.049     Document Type: Article

References (26)

1. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 67-74
2. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294 (2005) 1233-1239 Erratum in: JAMA 2008;299:899-900
3. Al-Mamgani A., van Putten W.L., Heemsbergen W.D., et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72 (2008) 980-988
4. Sathya J.R., Davis I.R., Julian J.A., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23 (2005) 1192-1199
5. Dearnaley D.P., Sydes M.R., Graham J.D., et al. RT01 collaborators. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 8 (2007) 475-487
6. Vora S.A., Wong W.W., Schild S.E., et al. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 68 (2007) 1053-1058
7. Swanson G.P., Hussey M.A., Tangen C.M., et al. SWOG 8794. Predominant treatment failure in postprostatectomy patients is local: Analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25 (2007) 2225-2229
8. Trock B.J., Han M., Freedland S.J., et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299 (2008) 2760-2769
9. Coen J.J., Zietman A.L., Thakral H., et al. Radical radiation for localized prostate cancer: Local persistence of disease results in a late wave of metastases. J Clin Oncol 20 (2002) 3199-3205
10. Buskirk S.J., Pisansky T.M., Schild S.E., et al. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: Evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 176 (2006) 985-990
11. Stephenson A.J., Scardino P.T., Kattan M.W., et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 25 (2007) 2035-2041 Erratum in: J Clin Oncol 2007;25:4153
12. Sella T., Schwartz L.H., Swindle P.W., et al. Suspected local recurrence after radical prostatectomy: Endorectal coil MR imaging. Radiology 231 (2004) 379-385
13. King C.R., and Kapp D.S. Radiotherapy after prostatectomy: Is there evidence for dose escalation out there?. Int J Radiat Oncol Biol Phys 71 (2008) 346-350
14. Buskirk S.J., Pisansky T.M., Schild S.E., et al. Salvage radiotherapy for rising prostate specific antigen after radical prostatectomy for prostate cancer: Dose response analysis. [abstract]. Int J Radiat Oncol Biol Phys 66 Suppl 1 (2006) S322
15. Amling C.L., Bergstralh E.J., Blute M.L., et al. Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point?. J Urol 165 (2001) 1146-1151
16. Valicenti R.K., Gomella L.G., Ismail M., et al. Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 42 (1998) 501-506
17. Anscher M.S., Clough R., and Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years. Int J Radiat Oncol Biol Phys 48 (2000) 369-375
18. Macdonald O.K., Schild S.E., Vora S.A., et al. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy. J Urol 170 (2003) 1833-1837
19. King C.R., and Spiotto M.T. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 71 (2008) 23-27
20. Cox J.D., Gallagher M.J., Hammond E.H., et al. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. J Clin Oncol 17 (1999) 1155
21. Anscher M.S. Adjuvant radiotherapy following radical prostatectomy is more effective and less toxic than salvage radiotherapy for a rising prostate specific antigen. Int J Cancer 96 (2001) 91-93
22. Feng M., Hanlon A.L., Pisansky T.M., et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys 68 (2007) 1417-1423
23. Cozzarini C., Fiorino C., Ceresoli G.L., et al. Significant correlation between rectal DVH and late bleeding in patients treated after radical prostatectomy with conformal or conventional radiotherapy (66.6-70.2 Gy). Int J Radiat Oncol Biol Phys 55 (2003) 688-694
24. Fonteyne V., De Neve W., Villeirs G., et al. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: The need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol 84 (2007) 156-163
25. Schiffner D.C., Gottschalk A.R., Lometti M., et al. Daily electronic portal imaging of implanted gold seed fiducials in patients undergoing radiotherapy after radical prostatectomy. Int J Radiat Oncol Biol Phys 67 (2007) 610-619
26. De Meerleer G., Fonteyne V., Meersschout S., et al. Salvage intensity-modulated radiotherapy for rising PSA after radical prostatectomy. Radiother Oncol 89 (2008) 205-213